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Abstract
HIV-1 CRF02_AG and subtype G (HIV-1G) account for most HIV infections in Nigeria, but their evolutionary trends have not
been well documented. To better elucidate the dynamics of the epidemic in Nigeria we characterised the gag and env genes
of North-Central Nigerian HIV-1 isolates from pregnant women. Of 28 samples sequenced in both genes, the predominant
clades were CRF02_AG (39%) and HIV-1G (32%). Higher predicted proportion of CXCR4-tropic (X4) HIV-1G isolates was
noted compared to CRF02_AG (p=0.007, Fisher’s exact test). Phylogenetic and Bayesian analysis conducted on our
sequences and all the dated available Nigerian sequences on the Los Alamos data base showed that CRF02_AG and HIV-1G
entered into Nigeria through multiple entries, with presence of HIV-1G dating back to early 1980s. This study underlines the
genetic complexity of the HIV-1 epidemic in Nigeria, possible subtype-specific differences in co-receptor usage, and the
evolutionary trends of the predominant HIV-1 strains in Nigeria, which may have implications for the design of biomedical
interventions and better understanding of the epidemic.
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Introduction
Two genetically distinct viral types of human immunodeficiency
virus (HIV) are known, HIV type 1 (HIV-1) and HIV type 2 (HIV-
2). HIV-1 is commonly encountered in sub-Saharan Africa, parts of
Asia and EasternEurope where HIV-1 prevalencerates arehigh(or
growing rapidly) as well as in most other parts of the world [1,2].
HIV-2 has been found mainly in infected individuals in West Africa
and is similar to HIV-1 in its tropism for cells of the immune system
and causation of illness that results from immune deficiency [1,2].
HIV-1 variants are classified into three groups (M, O and N) and
viral envelope sequences differ by up to 50% between these groups
[1].GroupMisresponsibleforthemajorityofinfectionsworldwide,
and is currently classified into 13 recognised subtypes or
subsubtypes (A1–A4, B, C, D, F1–F2, G, H, J, K) and 43 circulating
recombinant forms (CRFs). Unlike group M, O and N viruses are
restricted to west central Africa [1,2,3,4].
The global prevalence of HIV-1 appears to have stabilized at
0.8%, with 33 million people living with HIV/AIDS, 2.7 million
new infections, and 2.0 million AIDS deaths in 2007 [5]. The most
affected region is sub-Saharan Africa, bearing 67% of the global
burden [6]. The prevalence of various subtypes in West Africa is
not clear, but according to recent data, 16% of the world’s HIV-1
cases is in West Africa, with the dominant HIV-1 subtypes being A
(21%), G (35%), CRF02_AG (28%) and other recombinants (14%;
most of which is CRF06_cpx), leaving the other subtypes at less
than 1% each. The same data showed that the country with by far
the largest number of HIV-1 infections in the region is Nigeria,
where the epidemic is dominated by subtypes A (29%) and G
(54%) [6].
Nigeria is the most populous country in Africa with a population
of about 140 million and a growth rate of 3.2%. Based on the
national prevalence of 4.6%, it was estimated that 2.95 million
people in Nigeria were living with HIV/AIDS in 2008 [7]. In
1994, partial sequencing of four HIV-1 isolates demonstrated the
presence of subtype G viruses in Nigeria [8]. That same year, a
new strain of HIV-1 (HIV-1 IbNg), was isolated in Ibadan, Nigeria
[9]. By 1996, a full genome sequence of HIV-1 IbNg had been
obtained [10], and analysis proved IbNg to be a complex mosaic
genome with segments from subtype A and G, leading to the
designation CRF02_AG, of which IbNg is the prototype [11].
Recent studies have shown the predominance of subtypes G and
CRF02_AG in Nigeria [12,13,14,15,16]. In all, HIV-1 subtypes A,
B, C, D, F2, G, J and O have been identified in Nigeria, with
several recombinant forms, though in varying proportions
[15,17,18,19,20,21].
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fferent phenotypic or clinical properties, such as coreceptor
utilization, in vitro replication fitness, rate of disease progression,
biology of transmission, antigenicity, genital shedding, drug
resistance and mutational patterns [3,4,22,23,24,25,26]. Some of
the reported differences reflect variability in the env gene [3],
although differences have also been documented elsewhere
[27,28,29,30,31]. On the other hand, the Gag protein is an
important target of the immune system and cytotoxic T
lymphocyte (CTL) responses targeting this protein have been
shown to be associated with low viremia in some studies [32,33,34,
35,36,37].
North-Central Nigeria is one of the six geopolitical zones in
Nigeria, and it consists of six out of the 36 states as well as the
federal Capital Territory (FCT). As at 2005, North-Central
geopolitical zone had the highest HIV prevalence [38], yet the
molecular complexity has not been well documented. We thus
here sequenced and analyzed the genetic characteristics of gag
and env genes of HIV-1 isolates from North-Central Nigeria and
searched for trends between genetic characteristics and pheno-
typic properties. We also used statistical and phylogenetic tools to
model and estimate the origin and growth of CRF02_AG and
HIV-1G in Nigeria, which to the best of our knowledge is not yet
documented.
Results
Study population
Samples were obtained from 31 women who were part of a
survey conducted in 2007 to determine the demographic attributes
of and seroprevalence of HIV among pregnant women attending
antenatal clinics in North-Central Nigeria. The characteristics of
the population will be published elsewhere. For those analyzed for
this study, briefly, the mean age was 26.8 (range, 15 to 37) years,
mean age at first marriage was 21.6 (range, 12 to 31) years and all
were married. Most (24) of the women were living in urban
settlements. The women had at least secondary school education,
except three who only had primary school education and four
whose educational status is unknown. Most (17) of the women
were house wives or unskilled, while the rest had skilled (defined as
those with an occupation that requires at least a secondary school
education or two years of professional training) or of unknown
occupation. The mean number of pregnancies, abortion/miscar-
riages and children the women had are 2.61, 0.86 and 1.26,
respectively. All women discovered their HIV status within one
year of sample collection and were not on antiretroviral therapy.
Diversity
From the 31 samples, 29 gag and 30 env sequences were
obtained. Of the 29 gag sequences, 13 (44.8%) were CRF02_AG,
while 12 (41.4%) were HIV-1G. Also obtained was one gag
sequence each of HIV-1C, CRF06_cpx, HIV-1F2 and a
recombinant of HIV-1G and CRF02_AG. In the case of env
sequences, 15 (50.0%) were CRF02_AG, 10 (33.3%) were HIV-
1G, two were HIV-1C, one was HIV-1B, one was HIV-1F2 and
one was a recombinant of CRF02_AG and HIV-1G. Neighbour-
joining (NJ) tree analysis of gag and env sequences are shown in
Figure 1.
To enable better phylogenetic signal, where both gag and env
sequences were available, they were concatenated and subtyped.
Out of the 28 samples that was sequenced in both genes, 11
(39.3%) were CRF02_AG and nine (32.1%) were HIV-1G. Other
samples were one HIV-1C, one HIV-1F2 and six different types of
recombinants (Table 1). All nucleotides sequences are available
under GenBank accession numbers HM854072-HM854100 for
gag sequences and HM854042-HM854071 for env sequences.
Evolutionary relationship and signature pattern of
isolates from North-Central Nigeria
Gag and env sequences were compared with all the available
Nigerian sequences (corresponding to the coordinates of our
sequences) downloaded from the Los Alamos HIV Database
(Figure 2). The accession numbers of the downloaded sequences
are listed in Table S1. Using maximum likelihood methods, both
gag and env sequences intermingled with the available Nigerian gag
and env sequences. The CRF02_AG and HIV-1G clusters were
distinct, with the HIV-1G cluster consisting of two distinct sub-
clusters in the gag tree and three distinct sub-clusters in env tree. In
the env tree one of the three sub-clusters consisted of intermingled
HIV-1G and CRF06_cpx sequences, unlike in the gag tree where
CRF06_cpx sequences existed as a distinct clade. Prior to now
only one HIV-1F2 sequence has been documented in Nigeria
[13,21]. The identified HIV-1F sequence from the current study
was compared to the few available sequences from the Los Alamos
HIV database, using maximum likelihood method. The isolate
clustered in both genes with HIV-1F2 isolates from Cameroon
(data not shown).
Signature patterns were searched for between present isolates
and the previous Nigerian isolates, in order to identify possible
genetic features distinguishing isolates from this study compared to
those from earlier studies. There was no difference between the
signature patterns of study CRF02_AG gag sequences and previous
isolates. However, with respect to HIV-1G, there were differences
at HXB2 amino acids’ coordinates 158, 172, 214, 247, 285 and
314. In the case of env, we focused on the V3 loop due to its crucial
role in coreceptor usage. There was only one difference in
CRF02_AG sequences at position five of the V3 loop, an
asparagine in 80% of current study sequences compared to 56%
glycine for previous sequences. Two amino acid differences were
noted for HIV-1G sequences in the 14
th and 34
th V3 loop
positions, with phenylalanine and tyrosine in the study V3 loop
sequences at a frequency of 0.50 each; while isoleucine and
histidine were present in the previous sequences at frequencies of
0.85 and 0.75, respectively. The env V3 loop amino acid sequences
are shown in Figure 3a.
Genetic characteristics of isolates from North-Central
Nigeria
The main purpose of sequencing gag gene was to corroborate env
gene sequence data for the subtyping of isolates given previous
reports of complex diversity of HIV-1 isolates in Nigeria. We also
investigated characteristic sequence differences that may distin-
guish between the CRF02_AG and HIV-1G gag sequences in this
study. However, the only amino acid characteristic of note was the
presence of the H219Q substitution, which confers the greatest
replication potential to HIV-1 variants resistant to protease
inhibitors [39,40], in two (15.39%) of CRF02_AG and all the
HIV-1G isolates. The H219Q substitution seems to be a
polymorphism in HIV-1G as all previous isolates from Nigeria
and 93.8% worldwide harbour the substitution [21].
Coreceptor usage potential of isolates was predicted using the
net charge rule, the 11/25 rule, the combined criteria from the
11/25 and net charge rules as described by Raymond et al [41],
Geno2pheno web-based tool and specific position-specific scoring
matrix (PSSM) programme (also a web-based tool). Consistent
with previous observations [3], all the five methods predicted
CRF02_AG to be predominantly CCR5-using. There is no
Nigerian HIV-1G and CRF02_AG
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that all the five methods showed a trend toward higher usage of
CXCR4 in HIV-1G in comparison to CRF02_AG and individ-
ually, was found to be statistically significant (p=0.007, Fisher’s
exact test) using the combined criterion (Figure 3b), which has
previously been shown to perform best for the prediction of
CRF02_AG coreceptor usage [41].
The tetrapeptide motif on the tip of the V3 loop of env varies
among subtypes and this variability may have biological
importance [3,42]. Most (80%) of the isolates had the GPGQ
amino acid motif at the V3 loop, other motif sequences were
APGQ, GPGK and GPGR. As expected, the subtype B isolate
had the GPGR motif and non-B isolates predicted to be CCR5-
using (using the combined rule criteria) were significantly more
likely to have the GPGQ motif than those predicted to be
CXCR4-using (p=0.02, Fisher’s exact test).
Mutations in the V3 loop appear to play a key role in conferring
CCR5-tropic maraviroc-resistant phenotype [43]. None of our 20
predicted (combined criteria rule) CCR5-tropic sequences had the
combinations of mutations which has been previously described
and found in 7% of maraviroc-naive viruses [44,45,46].
Origin and demographic history of Nigerian CRF02_AG
and HIV-1G
To investigate the origin of CRF02_AG and HIV-1G in
Nigeria, we compiled data sets of Nigerian and reference
sequences for these subtypes from different geographic origins
for both env and gag regions under study. The Nigerian sequences
were derived from all of the available sequences (Table S1) in the
Los Alamos HIV database corresponding to our region of interest
(corresponding HXB2 coordinates 1234–1833 for gag data sets and
7068–7589 for env data sets), as well as those obtained from this
study that were subtype concordant in both regions. The
CRF02_AG gag and env data sets consisted of 28 and 33 sequences
respectively, with both data sequences dating from 1994 to 2007,
while the HIV-1G gag and env data sets consisted of 23 and 50
sequences respectively, with both data sequences dating from 1992
to 2007. The references sequences (Table S1) from other countries
were downloaded from the HIV Los Alamos data base by
accessing the HIV Sequence Alignments page of the database, and
downloading 2008 HIV-1 subtype reference of corresponding to
the HXB2 coordinates of the appropriate gene fragment.
Maximum likelihood phylogenetic analysis was carried out to
elucidate the relationship. Trees were rooted using HIV-1B
(HXB2) as outgroup. For clarity, tip labels are removed and the
branches for the Nigerian isolates are coloured in purple and the
reference sequences which are from other different countries are in
black. In the gag and env trees (Figure 4a and b), the Nigerian
CRF02_AG sequences were dispersed among other sequences
from other countries without any well-supported clade, suggesting
multiple independent entries of this subtype into Nigeria. The
Nigerian HIV-1G were also dispersed among other sequences
from other countries, suggesting that HIV-1G also made multiple
independent entries into Nigeria, however, they had one and two
well-supported clades (bootstrap $70%) in the gag and env trees
respectively (Figure 4c and d).
Bayesian methods for estimation of phylogeny under both strict
and uncorrelated lognormal molecular clock models was per-
formed on gag and env gene fragments of Nigerian HIV-1G using
Beast v1.5.3 [47]. Nigerian CRF02_AG had no well-supported
clade in the phylogenetic analysis and thus did not warrant further
analysis. The constant population size, exponential growth as well
as nonparametric Bayesian skyline plot tree priors were used for
inference. Regardless of the model involved, the two independent
runs of the Markov chain yielded similar results. Based on twice
the natural logarithm of Bayes factor [48,49], models enforcing a
relaxed clock over a strict clock were supported, regardless of gene
or subtype. Under the relaxed clock, the Bayesian skyline plot and
the constant population size were both supported (the alternative
model was not strongly supported over the null model), thus the
two models were adopted for making inferences. Models’ natural
logarithm of Bayes factor is shown in Table 2. It is noteworthy that
the exponential growth models did not fit the data sets, as
indicated by effective sample size (ESS) scores ,200 (data not
shown). All models used had ESS greater than 600.
Based on the gag data set, the relaxed Bayesian skyline plot and
the relaxed constant population size models estimated the
Nigerian HIV-1G’s most recent common ancestor (MRCA) to
1973.2 [HPDs 1953.4–1984.9] and 1957.3 [HPDs 1867.4–
1982.9], respectively. Still with both models, based on the env
data set, the MRCA was traced to 1971.6 [1960.1–1980.3] and
1969.5 [HPDs 1955.6–1979.3], respectively. Date of the most
common recent ancestor and parameters estimated for each model
are shown in Table S2, while the evolutionary rate and parameters
estimated for each model are in Table S3. Due to the likely
scenario of multiple independent entries (from neighbouring
countries) caution should be taken in the interpretation, as these
most recent ancestors is not necessarily the ancestor of Nigerian
isolates alone nor a reflection of how early the subtypes has been in
Figure 1. Neighbor-joining trees for (a) gag and (b) env sequences. The 29 gag and 30 env sequences were each aligned with reference
sequences from the Los Alamos HIV database. The percentage (only values .70%) of replicate trees in which the associated taxa clustered together
in the bootstrap test (1000 replicates) are shown. The evolutionary distances were computed using the Maximum Composite Likelihood method in
Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0.2. Study sequences’ branches are in bold.
doi:10.1371/journal.pone.0017865.g001
Table 1. Genetic diversity of HIV-1 isolates from
antiretroviral-naive pregnant women from North-Central
Nigeria.
GAG/ENV
subtype
Number of
Samples %a
Concatenated Sequences
‘subtype’
C/C 1 3.6 C
CRF02/CRF02 11 39.3 CRF02
F2/F2 1 3.6 F2
G/G 9 32.1 G
CRF02/B 1 3.6 CRF02 B
CRF02/CRF02 G 1 3.6 CRF02
CRF06/CRF02 1 3.6 CRF02
G/C 1 3.6 G C
G/CRF02 1 3.6 G CRF02
G CRF02/CRF02 1 3.6 G CRF02
G/# 1
#/CRFF02 1
#/G 1
aPercentage of the 28 samples with both gene fragments sequenced.
#Gene fragment not amplified.
doi:10.1371/journal.pone.0017865.t001
Nigerian HIV-1G and CRF02_AG
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17865Nigerian HIV-1G and CRF02_AG
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17865the country. Still with the Bayesian analysis the origin of the
Nigerian transmission clades observed in figure 4 c and d was
traced to 1974 with the gag data set and 1981 with the env data set
(Figure 5). Thus we could speculate the possible presence of the
subtype in the country by or earlier than the early 1980s, involving
a three phase growth. The three phase growth consists of a pre-
1985 constant population, an exponential growth from 1985 to
early 1990s, and a slower post early 1990 growth. But these
speculations by the Bayesian skyline plot needs confirmation
through the demonstration of these subtypes in archived samples,
as there could be several possible explanations since we are not
dealing with a closed population, more so since the constant
population demographic model cannot be rejected.
Discussion
Nigeria is the home to the second largest population of people
living with HIV/AIDS, with this large number of infected people,
routine and systematic surveillance of the genetic diversity of HIV
is necessary. Thus our carrying out an exploratory study to
characterize gag and env signature sequences associated with the
epidemic in Nigeria was in order, especially with the need for
new/novel therapeutic and prophylactic strategies that target these
important genes. Furthermore, a detailed characterization of the
introduction and growth of HIV-1 in Nigeria is lacking and
relevant data could be useful for designing strategies to prevent the
spread of HIV-1 and future epidemics. Hence we explored the
genetic variability of HIV-1 in North-Central Nigeria which is the
geopolitical zone with the highest HIV prevalence rate [38], and
also explored the temporal genetic variation of Nigerian gag and
env genes of CRF02_AG and HIV-1G.
Consistent with data from previous studies in Nigeria from other
regions [12,13,14,15,16], we observed that the HIV epidemic in
North-Central Nigeria is driven predominantly by CRF02_AG
and HIV-1G. Of 28 samples sequenced in gag and env genes, 6
(21%) had discordant subtypes between the two genomic regions,
as observed with recent studies in Nigeria [16,20]. These
discordant samples may represent new recombinant forms or
coinfection/superinfection (which could ultimately also result in
the formation of unique recombinant forms). Based on the
relatively small gene fragments we sequenced, we cannot make an
inference as to the true nature of these discordant samples. Over
20% of the current HIV-1 infections in Africa are estimated to
represent recombinant strains, and yet the possible consequences
of the emergence of recombinant HIV-1 strains is not yet
understood [50]. Beside CRF02 and HIV-1G, we isolated other
subtypes, all of which have long been known to exist in Nigeria,
though to a relatively low prevalence. Thus the complexity of the
HIV-1 pandemic in Nigeria may still be well underrepresented.
Using Maximum likelihood method we observed that our
isolates at both gag and env genes intermingled with previous
Nigerian ones with no founder effect noted. The signature pattern
analysis also showed similarities between our isolates and previous
Nigerian isolates. Subtype G radiation (sub-clustering) was seen in
both the gag and env trees as observed previously [15,16,20,51].
Because the sub-cluster corresponding to the prototypic subtype G
constitute minority of the sequences, the sub-cluster containing
majority of the subtype G sequences was classified as G9
[15,20,51]. The relationship of this ‘‘Nigerian subtype G’’
(denoted as G9) to the prototypical subtype G for future
immunological and vaccine research in Nigeria, may only be
assessable through full-length genome amplification [16]. The
HIV-1F2 isolate noted in this study is only the second isolate of
this clade from Nigeria. It is interesting to note that the first isolate
was from Jos which is a city in North-Central Nigeria [13,21]. This
sequence closely clusters with Cameroonian sequences and might
have been introduced into Nigeria from Cameroon. This is not
surprising as Cameroon shares a border with Nigeria and HIV-
1F2 is presumed to have originated in Cameroon [52].
The H219Q substitution in the cyclophilin A (CypA) binding
loop in gag seen in all Nigerian HIV-1G and 93% of all isolates
Figure 2. Relationship of study isolates to previous Nigerian HIV-1 isolates. Maximum likelihood trees of (a) gag and (b) env isolates
(indicated with pebbles at tip) and previous Nigerian gag and env isolates (obtained from the Los Alamos HIV database), respectively, using the GTR
model which was the ‘best fit’ for both data sets as determined by the FindModel tool of the Los Alamos HIV database.
doi:10.1371/journal.pone.0017865.g002
Figure 3. Env V3 amino acid sequences and CXCR4 usage potential of isolates. (a) Env V3 amino acid sequences; each sequence is flanked
by its sample number on the left and the subtype on the right. (b) A chart of relative CXCR4 usage prediction based on net charge rule [n.charge], the
11/25 rule, the combined criteria from the 11/25 and net charge rules [combined] as described by Raymond et al (2009), the web-based specific
position-specific scoring matrixes (PSSM) programme and the web-based Geno2pheno tool.
doi:10.1371/journal.pone.0017865.g003
Nigerian HIV-1G and CRF02_AG
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subtype. In the development of high level HIV-1 resistance against
protease inhibitors, H219Q substitution in Gag emerges earlier
than substitutions in protease [39], and has been shown to confer
the greatest replication potential to HIV-1 variants resistant to
protease inhibitors [40]. It has been observed that there is
Figure 4. Relationship between Nigerian isolates and reference sequences from other parts of the World. Maximum likelihood analysis
of (a) CFR02_AG gag, (b) CFR02_AG env, (c) HIV-1G gag and (d) HIV-1G env sequences. Each tree shows the relationship between Nigerian sequences
(purple) and reference sequences from other countries (black), using the GTR best model as determined by FindModel tool of the Los Alamos HIV
database. Trees were rooted using HIV-1B (HXB2) as outgroup. Bootstrap resamplings (1000 replicas) was used to assess robustness and values $70
are indicated with asterisk.
doi:10.1371/journal.pone.0017865.g004
Nigerian HIV-1G and CRF02_AG
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inhibitors [53]. It is possible that the H219Q polymorphism in
HIV-1G may contribute to this observation. We also noticed other
polymorphisms in the CypA binding loop at positions 218 and 222
that may have unknown effect on CypA binding and viral
replication. Though the CypA binding loop of HIV-1B has been
modelled [40], there is a need for an in-depth molecular modelling
of the CypA binding loop of HIV-1G, which seems to be different
from HIV-1B. Furthermore, the effectiveness of protease inhibi-
tors in geographic areas where CRF02_AG and HIV-1G
predominate may require careful monitoring as our data suggests
that these subtypes may have lower genetic barrier for an
important compensatory mutation in gag once protease resistance
emerges.
Along with CD4, HIV-1 requires a chemokine receptor, CCR5
or CXCR4, as an entry co-receptor, and differential coreceptor
selectivity is an important determinant of viral diversity and
pathogenesis. Besides, the interest in HIV tropism has recently
risen with the development of CCR5 antagonists as clinically
applicable anti-HIV agents [54,55,56]. Though the ‘‘gold
standard’’ for characterization of HIV-1 tropism is a recombinant
virus phenotypic entry assay, genotypic methods based on the V3
sequence have been successful with HIV-1B, and could be an
easier and more cost effective option and might prove useful as
screening strategy in clinical practice [54,57]. There has been
more success in the determination of tropism of non-B viruses as a
result of modifications/improvements in prediction rules and
bioinformatic tools [41,58]. Our prediction on CRF02_AG
isolates is consistent with previous observation [3], and thus shows
that individuals infected with CRF02_AG are likely to benefit
from coreceptor antagonists like maraviroc, though high CXCR4
usage has been observed in late infections involving CRF02_AG
[59]. However, individuals infected with HIV1-G may not equally
benefit since all the five methods predicted higher usage of
CXCR4 in HIV-1G in comparison to CRF02_AG, especially the
combined criterion which has previously been shown to best
predict CRF02_AG coreceptor usage [41,59]. Our study thus
highlights a need for better characterization of HIV-1G tropism,
because more data is clearly needed, especially since HIV-1G
makes up 6.3% of the global HIV infections [60]. Nevertheless,
our study provides evidence that this subtype may have a higher
proportion of X4 variants compared to CRF02_AG and other
non-B subtypes although phenotypic characterization is clearly
warranted.
Two known mutational pathways of viral escape from CCR5
antagonists are selection of R5X4/X4-tropic viruses or develop-
ment of resistance to the antagonists [61]. None of the predicted
CCR5-using isolates from this study had the combination of
mutations that confer resistance to coreceptor antagonists, which
suggests that maraviroc will be relevant in the management of
CCR5-using HIV-1 in Nigeria. However, coreceptor usage ability
of patients’ viral population will clearly be required before clinical
administration, especially with the significant presence of HIV-1G
which by our study shows to have higher potential for CXCR4
usage.
Phylogenetic inference from molecular sequences is becoming
an increasingly popular tool to trace the patterns of pathogen
dispersal, especially for rapidly evolving RNA viruses
[62,63,64,65]. Here we utilized a combination of maximum
likelihood and Bayesian methods to decipher the epidemiology
and evolution of the predominant HIV-1 clades in Nigeria from
sampled gene sequence data. The exponential models did not the
fit our data sets which could be due to insufficient information in
the data to accommodate a complex tree model, as has been
observed previously [66], or because the Nigeria epidemic cannot
be explained using an exponential growth model. We found the
Bayesian skyline plot a useful method for estimating ancestral
population dynamics from our sample of molecular sequences as
shown previously [67]. The approach showed that both clades
made multiple entrances into the country to establish the present
day epidemic, similar to subtype C in Zimbabwe [64], and HIV-
1G probably had been in the country since the early 1980’s or
earlier. These findings are consistent with what is known about
HIV-1 origin in Nigeria, as the first HIV positive person was
identified in 1983 [38]. Based on the shape of the skyline plots, we
could extrapolate that HIV-1G in Nigeria, had a three phase
growth. The first phase involved a pre-mid 80s constant
population, fast growth for about 9 years (from around 1985 to
1993) and a much slower phase from around 1993 to 2007.
However, the error intervals (HPDs) especially with gag data set
and Bayes factor do not allow us to exclude that, in average, the
epidemic in Nigeria has been constant over time, which can even
suggest a decrease in the last decade. Since HIV-1G constitute
substantial part of the overall HIV-1 epidemic in Nigeria, the
overall growth of HIV-1 may be similar. Thus it is noteworthy that
we observed that the growth rate became slower from around
1993, which is the year in which the present Nigerian democracy
began. It may be possible that since 1993, as a result of democracy
and increased socio-political stability and increase in media
awareness, the HIV-1 growth rate declined. Our study, not unlike
studies in other countries, suggests that complex socio-political and
economic changes can dramatically influence the epidemiology of
a newly introduced pathogen in a population [64,68]. Though
both the gag and env data sets produced results that are
corroborative, as shown by the Bayesian skyline plots (Figure 5),
we still need to produce a more detailed sampling in order to
capture the earlier and more recent population demography. The
lack of resolution (and high HPDs) especially with gag data set is
most likely due to the fact that the sample used is small, both in
sequence size as well in temporal distribution.
In conclusion our study showed that there is a high genetic
complexity of HIV-1 in North-Central Nigeria which is predom-
inated by CRF02_AG and HIV-1G. We observed apparent
differences in gag with respect to a mutation that could confer
increased replication capacity in the presence of protease inhibitor
resistance mutations, potential differences in coreceptor usage and
Table 2. Natural logarithm Bayes factors between different
models.
Data set H1/H0 BSP relaxed CS relaxed BS strict CS strict
HIV-1G GAG BSP relaxed - 21.337 4.903 4.776
CS relaxed 1.337 - 6.24 6.113
BS strict 24.903 26.24 - 20.127
CS strict 24.776 26.113 0.127 -
HIV-1G ENV BSP relaxed - 22.089 7.582 6.608
CS relaxed 2.089 - 9.671 8.698
BS strict 27.582 29.671 - 20.973
CS strict 26.608 28.698 0.973 -
BS: Bayesian Skyline plot; CS: constant population size; relaxed: relaxed
molecular clock; strict: strict molecular clock Evidence against H0 (null) model is
assessed in the following way; 0–6 indicates positive evidence for H1
(alternative) model, .6 indicates strong evidence for H1. The H0 models are in
the first row while the H1 models are in the first column.
doi:10.1371/journal.pone.0017865.t002
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reconstructed by Bayesian skyline plot. The first arrow from the left indicates the time of the MRCA. The other arrows indicate the estimated origin of the
correspondingNigerianclade (indicatedbytheRomannumeral) inthe trees in Figure 4 c andd.HPDs(95%) aregivenin parenthesis beside each estimate.
doi:10.1371/journal.pone.0017865.g005
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CCR5 antagonists. Lastly we showed that Nigerian HIV-1
demography involved multiple introductions, a phase of early
growth (pre-democracy) and phase of stabilisation (post-democ-
racy) or even decrease of the HIV epidemic. Our observation on
genetic complexity may be limited by the relatively small
numbers of samples sequenced and small fragments analyzed
rather than full length genomes. Also the observation on
coreceptor usage is limited by the absence of phenotypic/
functional assays, patients’ CD4 counts and clinical staging of the
infection in the current study. Furthermore, the scarcity of
Nigerian HIV-1 sequences limits the analytic and predictive
power of the Bayesian and phylogenetic methods used. We
therefore recommend phenotypic assay based study on HIV-1G
tropism as well as more surveillance studies involving archive and
recent strains and full-length genome sequencing in order to
better understand HIV diversity in Nigeria.
Materials and Methods
Ethics statement
The institutional ethics review board of the Ahmadu Bello
University Teaching Hospital, Zaria, Nigeria and the ethics
boards/committees of the various facilities involved approved the
study and informed consent was received from each participant.
Study population
The samples sequenced in this study was derived from a survey
conducted from August to November 2007 to determine the
demographic attributes and seroprevalence of HIV among
therapy-naı ¨ve pregnant women attending antenatal clinics of
four health facilities in North-Central Nigeria. The facilities
involved were: Federal Medical Centre, Markudi in Benue;
Bwarri General Hospital, in FCT; General Hospital, Minna in
Niger; and Church of Christ in Nigeria (COCIN) Community
Development Program [CCDP] Hospital, Panyam in Plateau.
Relevant primary study information on the survey will be
published elsewhere.
RNA extraction, reverse transcription, and PCR
amplification of gag
RNA was extracted from plasma using the QIAamp Viral RNA
mini kit (Qiagen, Heiden, Germany) according to the manufac-
turer’s instructions. The RNA template and 100 ng of primers
(random hexamers) were heated at 65uC for 5 min, chilled at 4uC
for 1 min and reverse transcribed at 50uC for 60 min, followed by
55uC for 60 min and finally held at 70uC for 15 min in a 20 ml
reaction volume containing, 56 reaction buffer, 10 mM dithio-
threitol, 0.5 mM each deoxynucleoside triphosphate, 40 U RNase
OUT (Invitrogen) and 200 U Superscript III reverse transcriptase
(Invitrogen). RNaseH (Invitrogen) was subsequently added to the
reaction and incubated at 37uC for 20 min. The cDNA was stored
at 220uC until needed.
The p24 gag region was amplified from cDNA with G00 (59-
GACTAGCGGAGGCTAGAAG-39; positions 764 to 782, ac-
cording to HxB2 coordinates [69] and G01 (59-AGGGGTCG-
TTGCCAAAGA-39; positions 2,264 to 2,281) as outer primers.
G25 (59-ATTGCTTCAGCCAAAACTCTTGC-39; positions
1,867 to 1,889) and G60del39G( 5 9- CAGCCAAAATTACCC-
TATAGTGCA-39; positions 1,173 to 1,197) were the inner
primers. The PCR conditions for both the first and second round
reactions were initial denaturation at 95uC for 10 min, followed by
35 cycles at 94uC for 30 s, 45uC for 35 s, and 72uC for 60 s.
RNA extraction, reverse transcription, PCR amplification
and cloning of env
RNA extraction, and reverse transcription were carried out as
for the gag gene, except that primer OFM-19 [70] was used. The
PCR conditions were as described previously [71].
Cloning was modified from Singh et al [72], using the TOPO
TA cloning Kit (with pCR2.1-TOPO vector) with One Shot
TOP10 chemically competent E. coli (Invitrogen).
Visualisation of amplified products and sequencing and
sequence analysis
Amplified products were visualised on 1% agarose gels and
PCR products or clones sequenced using the inner primers as
described previously [72]. Sequences were assembled and edited
with Sequencher 4.8 and aligned with reference sequences
obtained from Los Alamos HIV database using Bioedit 5.0.9
[73], with manual editing as necessary. The aligned trimmed
products of the gag region corresponds to positions 1,234 to 1,833
(600 bp; Gag residues 149 to 348), while aligned trimmed products
of the env region corresponds to positions 7,068 to 7,616 (549 bp;
C2–C4). Phylogenetic analyses were conducted using the Maxi-
mum Composite Likelihood method in Molecular Evolutionary
Genetics Analysis (MEGA) software version 4.0.2 [74] and
bootstrap consensus trees were inferred from 1,000 replicates.
To identify recombinants, analysis was performed on the gag, env,
and concatenated sequences (where samples were amplified on
both genes), using a combination of Recombinant Identification
Program, RIP 3.0 from the Los Alamos HIV database and
SimPlot version 3.5.1 [75]. Recombinants were further confirmed
with Neighbor-Joining (NJ) trees using the estimated breakpoint
obtained from the SimPlot analysis.
Differences in signature patterns between samples in this study
and those from previous ones in Nigeria were identified using
Viral Epidemiology Signature Pattern Analysis (VESPA) software
[76,77]. Coreceptor utilization was predicted using three rules and
two web-based bioinformatics tools. The rules were the net charge
rule [78], the 11/25 rule [79] and the combined criteria from the
11/25 and net charge rules as described by Raymond et al [41].
The web-based tools used were the Geno2pheno [80] and
position-specific scoring matrix (PSSM) programme [58,81].
Graphical representation of conserved amino acids was done
using a web-based sequence depiction tool, WebLogo 3.0 software
[82].
Evolutionary analysis
The best fitting nucleotide substitution model was evaluated
using a web-based tool, FindModel [83]. The model chosen for the
alignments was the GTR (general time reversible model).
Maximum likelihood (ML) phylogenies were estimated for each
dataset under the model, starting with a NJ starting tree and using
SPR (subtree pruning and regrafting) heuristic search algorithms.
Calculations were performed with Phylogenetic Analysis Using
Parsimony (PAUP*) 4.0b10 written by David L. Swofford.
Statistical support for ML phylogeny structures was evaluated by
bootstrapping analysis of the original sequence alignments (1,000
NJ replicates). Trees were rooted by outgroup (HxB2) and
presented using the program FigTree 1.3.1 written by Andrew
Rambaut. Bayesian estimates of phylogeny were obtained using
BEAST v1.5.3 [47], under both strict and relaxed lognormal
molecular clock models. All analysis was performed under the
HKY nucleotide substitution model and SRD06 model used for
partitioning into codon positions. Two parametric models
(constant population and exponential growth) and one nonpara-
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inference. For each model, two independent runs of the Markov
chain were performed. For the gag gene, each Markov chain
Monte Carlo (MCMC) run was 20,000,000 steps long, while for
the env gene, MCMC runs were 30,000,000. Both were sampled
every 10,000 steps. The Effective Sampling Size (ESS) was
calculated by combining the output of the two runs (that both
converged and mixed properly) using BEAST v1.5.3’s Log
Combiner, excluding an initial burn-in of 10% for each chain
and viewed in Tracer v1.5.0 (written by DRUMMOND, A. J. and
RAMBAUT, A.). The ESS value of .200 was taken as a sufficient
level of sampling. Model comparison was achieved by calculating
Bayes factor [48].
Statistical analysis
To analyse difference in predicted CXCR4 usage of
CRF02_AG and HIV-1G, the results of the coreceptor predictions
according to each rule/tool were analysed for differences using
Fisher’s exact test, as implemented in GraphPad Prism version
5.00 for Windows, GraphPad Software, San Diego California
USA, www.graphpad.com.
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